Vertex may have pivoted away from the space, but candidates in development by Arrowhead/Takeda, Wave, Korro and others could ...

RBC Capital analyst Charles Weston maintained a Hold rating on Siegfried Holding AG on October 25 and set a price target of CHF1125.00. The company’s shares closed last Thursday at $965.00, equals to ...

The latest health news highlights major biotech and pharmaceutical updates, including Septerna's market debut, Sanofi's ...

The World Health Summit 2024 broke new ground in illuminating how communities are tackling the health impacts of climate ...

Recent developments in healthcare cover a broad spectrum of issues: an analysis reveals that weight-loss drugs like Wegovy do ...

Sanofi attributed its double-digit growth to growth in vaccines, particularly its latest flu jab. Another major revenue ...

Health-care companies fell after mixed earnings. HCA Healthcare shares fell after the hospital operator logged third-quarter earnings short of estimates. Sanofi shares rallied after the French drug ...

Sanofi (SNY) has released an update. Sanofi reported a robust 15.7% growth in sales for Q3 2024, driven by strong performances in its vaccine ...

Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase ...

Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

Eli Lilly (LLY) said a study of its drug Ebglyss showed it was able to improve skin and itch in patients with atopic ...